blood brain News
-
Nanoparticulate Peptide Delivery Exclusively To The Brain Produces Tolerance Free Analgesia
There is pharmacological evidence of activity of MET enabled enkephalin in morphine-tolerant animals. We believe the preliminary data from these early animal studies of NES100 support our belief that Envelta™ may have comparable preclinical activity to morphine in all animal pain models tested without the drug seeking, respiratory depression, and tolerance associated with opioids. ...
-
Leucine-Enkephalin as a Novel Analgesic: Efficacy and Safety in Pre-Clinical Models
Endogenous peptides with analgesic potential include endorphins via the mu receptor, dynorphins via the kappa receptor and enkephalins via the delta receptor. Kappa and delta opioid agonists have been shown to provide analgesic benefit while sparing toxic mu agonist toxicity1 . Preclinical data supports analgesia from enkephalin without significant opioid tolerance, or drug liking. Unfortunately, ...
-
Infuseon Therapeutics, Inc. CMO Discusses Delivery of Therapeutics Directly to the Brain at NeuroTech Investing and Partnering Conference
infuseon therapeutics, Inc., the company that enables therapeutic delivery to the brain, announces that Dr. Michael A. Vogelbaum, Chief Medical Officer and co-inventor of the Cleveland Multiport Catheter system, will be speaking at the NeuroTech Investing and Partnering Conference taking place in Boston on Thursday, April 7. Dr. Vogelbaum, a brain surgeon at Cleveland Clinic, will be part of the ...
-
Clinical study authorised in Sweden for the investigation of CDNF and Renishaw drug delivery system in Parkinson`s patients
The Medicines Agency of Sweden, MPA, has authorised Herantis Pharma Plc and Renishaw plc's randomised, placebo-controlled Phase 1-2 clinical study, for the investigation of Cerebral Dopamine Neurotrophic Factor (CDNF) and Renishaw's chronic drug delivery system, in Parkinson's patients. The first study site to start patient recruitment will be the Karolinska University Hospital in Stockholm, ...
By Renishaw plc
-
Kurve Therapeutics, Innovative Medtech and Specialty-Drug Company Focused on Treating Neurodegenerative Diseases, Files Regulation A Offering
Kurve Therapeutics, a next-generation medtech innovator focused on developing treatments for neurodegenerative diseases, announced it has filed a Form 1-A preliminary offering circular with the U.S. Securities and Exchange Commission (SEC) for a $50 million funding round [kurvetx.com/offering-circular]. Investment opportunities are now open to public investors for offers starting at $580 for 100 ...
-
Combines mesenchymal stem-cell-based product, with Kurve’s intranasal drug delivery technology
Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, and Kurve Therapeutics, a next-generation medtech and drug formulation company, today announced positive preclinical study results for intranasal administration of a cell-based oncolytic virus bearing product. The results ...
-
Orion Receives Funding to Advance its Lead GPCR-Targeted Therapeutic
Orion Biotechnology Canada Ltd., a clinical stage company unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs) with a novel drug modality, proven discovery platform and best-in-class molecules, today announced that it is receiving advisory services and conditional funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). The ...
-
Preclinical development of a novel radiopharmaceutical bioconjugate with the potential to cross the blood brain barrier
CIS Pharma and the University of Applied Sciences in Basel were granted a two-year research program by the Swiss Nanoscience Institute, SNI, to develop a nanobody-radionuclide conjugate, currently at preclinical stage. The bioconjugate is based on CIS Pharma’s polymer drug carrier technology and is developed to diagnose and treat B7H3-positive forms of cancer. The target plays a role in the ...
-
Biomodex Teams Up with Physicians at Three of the World’s Top Medical Centers to Develop a Cutting-Edge Training Solution for Treatment of Ischemic Stroke
BIOMODEX, a pioneering digital health company that offers a unique and enhanced 3D printed solution for physician training, announced today the company has partnered with two of the top medical centers in France and a world-class health system in the United States to develop EVIAS Plus - an innovative training solution for treatment of ischemic stroke. Ischemic stroke accounts for about 87 ...
By BIOMODEX
-
Transformative Dementia and Alzheimer’s treatment company Kurve Therapeutics launches $50m equity crowdfunding raise
Next-generation Medtech innovator Kurve Therapeutics begins an equity crowdfunding journey with its $50 million Regulation A+ raise. Private investors can now invest in a company aiming to disrupt and transform a $1.3 trillion dementia market alone while benefiting millions living with neurodegenerative diseases. Diseases like Dementia and Alzheimer’s afflict millions of people across the ...
-
Kurve Therapeutics Announces Next-Gen Technology Designed for a New Approach to Treating CNS Disorders
Kurve Therapeutics has succeeded in bypassing the blood-brain barrier with their patented Controlled Particle Dispersion® (CPD) technology, creating new hope in the treatment of central nervous system disorders. The company urges CNS researchers to reach out for collaboration in providing care for this very large global population. Led by a team of experienced entrepreneurs with ...
-
CanaQuest Launches Mentanine (R) (Cannabidiol + IP Formula) in the US via www.canaqueststore.com, Supported by Western University Pre-Clinical Trials Targeting Anxiety, Depression and PTSD
Canaquest Medical Corp (OTC Pink:CANQF) (the "Company" or "CanaQuest"), an award-winning, Clinical Stage/Life-Sciences company focused on drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors, today announced its US launch of all-natural Mentanine® (cannabidiol "CBD" + IP, Omega-3s, DHA, EPA formula) in ...
-
Canaquest Launches Mentanine (Cannabidiol + IP Formula) in the US via www.canaqueststore.com, Supported by Western University Pre-Clinical Trials Targeting Anxiety, Depression and PTSD
Canaquest Medical Corp (OTC PINK:CANQF) (the “Company” or “CanaQuest“), an award-winning, Clinical Stage/Life-Sciences company focused on drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors, today announced its US launch of all-natural Mentanine (cannabidiol “CBD” + IP, Omega-3s, ...
-
DiamiR Receives USPTO Notice of Allowance For Key Patent Covering the Use of Circulating Brain-Enriched microRNA Biomarkers for Monitoring of Brain Aging; Provides Update on Its Patent Portfolio
DiamiR, a developer of innovative blood-based diagnostic tests for neurodegenerative and other diseases, today announced that it has received a notice of allowance from the United States Patent & Trademark Office (USPTO) for U.S. Patent Application No. 16/044,279 entitled "miRNA-based methods for detecting and monitoring aging." The patent covers the use of methods developed by DiamiR based ...
By DiamiR
-
Flowonix Medical and Cerebral Therapeutics Announce Fifth Implant of First-of-a-Kind Implantable Drug Therapy to Treat Patients with Refractory Epilepsy
Flowonix Medical, Inc. and Cerebral Therapeutics, Inc. announced today the successful implant of the fifth patient in the ADDRESS (Australian Direct Drug Administration for Refractory Epilepsy) trial. The jointly developed therapy features a micro-infusion device which tightly controls drug delivery to a region of the brain for patients with medically refractory epilepsy. "The study ...
-
DiamiR Announces Additional $345,000 Funding from the NIH for Development of CogniMIR
DiamiR, a developer of innovative blood-based diagnostic tests for neurodegenerative and other diseases, announced today that the National Institute on Aging (NIA) of the National Institutes of Health (NIH) has awarded DiamiR $345,000 in supplemental funding under the ongoing Small Business Innovation Research (SBIR) Phase IIB grant of $2,800,000 awarded in 2017. The award will further support ...
By DiamiR
-
Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted eight Sangamo abstracts for presentation at the 25th ASGCT Annual Meeting being held May 16-19, 2022, in-person in Washington, D.C. and in a virtual format. Presentations will focus on the progression of Sangamo’s pre-clinical ...
-
1 out of 10 survive cardiac arrest, a new device under FDA review hopes to change that
KEY POINTS Cardiac arrest is one of the leading causes of death in the U.S. and globally. It has a survival rate of 1 in 10 people with current treatment. The Neurescue device is designed to increase blood flow to the brain and heart during life-threatening emergencies such as cardiac arrest. Cardiac arrest is one of the leading causes of death around the world, ...
By Neurescue
-
Lauren Sciences LLC awarded second grant for LAUR-401 from Voices Against Brain Cancer
New York, New York, February 7, 2017 -- Lauren Sciences LLC, the private New York biotechnology company developing transformative V-Smart™ Nanomedicines for brain diseases, today announced the award of its second grant from Voices Against Brain Cancer (VABC). VABC grant will support Lauren Sciences continued development of LAUR-401, its novel V-Smart™ Nanomedicine for Glioblastoma ...
-
Elucid Appoints Dr. Michael Lesh to Board of Directors
BOSTON, November 3, 2022 – Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to characterize cardiovascular disease, today announced the addition of Michael D. Lesh, MD, FACC, to its Board of Directors. “We look forward to what Dr. Lesh will bring to the board with his extensive background as a cardiologist, medtech ...
By Elucid
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you